The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib
Journal of Dermatological Treatment, Ahead of Print.
ConclusionsOur data show that KLHTT has anti-neutrophilic inflammatory effects in inhibiting ROS generation and cell adhesion. KLHTT also mitigated NET formation, mainly via an ROS-dependent pathway. In addition, KLHTT reduced neutrophil infiltration and improved the severity of IMQ-induced psoriasis-like skin inflammation in mice. Therefore, KLHTT may prove to be a safe and effective psoriasis therapy in the future.Graphical abstract
Conclusion: Nd:YAG laser represents an effective and safe modality for nail psoriasis treatment and dermoscopy is a useful tool for treatment efficacy assessment. PMID: 31524008 [PubMed - as supplied by publisher]
Conclusions: Fixed combination HP 0.01%/TAZ 0.045% lotion formulation utilizing innovative polymeric emulsion technology and optimal selection of solvents/emollients/humectants, has recently been developed. Features inherent in the technology translate into rapid, sustained efficacy, low irritation and good patient acceptance. PMID: 31522563 [PubMed - as supplied by publisher]
Biologics for psoriasis often lose effectiveness over the long-term, resulting in discontinuation of therapy. What factors and comorbidities might impact drug persistence?The British Journal of Dermatology
Authors: Hooper D Abstract Psoriasis is a common, chronic inflammatory skin disease that can affect any part of the body. It is a highly visible condition with symptoms that include the appearance of red, thick, scaly patches on the arms, legs, trunk, soles of the feet, palms, and nails, but most commonly on the elbows, knees, and scalp. PMID: 31524995 [PubMed - in process]
Publication date: Available online 16 September 2019Source: Regulatory Toxicology and PharmacologyAuthor(s): Michael Santostefano, Danuta Herzyk, Diana Montgomery, Jayanthi WolfAbstractTildrakizumab (also known as MK-3222), is a high-affinity, humanized, immunoglobin G1κ monoclonal antibody targeting the p19 subunit of interleukin-23 recently approved for the treatment of moderate to severe plaque psoriasis in the US, Europe, and Australia. The safety profile of tildrakizumab was characterized in nonclinical studies using a pharmacologically relevant cynomolgus monkey model. In repeat-dose toxicity studies, cynomolgu...
This cohort study evaluates clinical utility of monitoring serum levels of ustekinumab in patients with psoriasis.
In 2019, the efficacy and safety of biologic therapy offer most patients with psoriasis the opportunity to achieve safe and complete or nearly complete clearance of skin lesions. A major obstacle remains across the world, however, in getting access to the best psoriasis medications, owing to high cost and/or lack of adequate health insurance. Indeed, it is commonplace for insurance companies and national regulatory authorities to control use of biologics to reduce overall costs to health care. More specifically, patients with psoriasis often have to experience treatment failure with cheaper, less effective, and less safe n...
Conclusions: We demonstrated achievable HDR-BT for our first case of nail bed psoriasis. The end-to-end exercise was an efficient methodology to evaluate new feasibility for this technique. Real-time dose monitoring using MOSFET was an effective and reliable tool to ensure treatment quality and patient safety. PMID: 31523241 [PubMed]
Sabrina Speaks, now 23, was diagnosed with plaque psoriasis when she was 12. The immune disorder has left 90% of the North Carolina resident's body covered in white scaly patches and daily pain.